UBS Group
PROF

UBS Group’s Profound Medical PROF Stock Holding History

UBS Group’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$367K Sell
55,224
-25,884
-32% -$174K ﹤0.01% 6430
2026
Q1 		$526K Buy
81,108
+75,603
+1,373% +$522K ﹤0.01% 6049
2025
Q4 		$43.3K Buy
5,505
+5,303
+2,625% +$34.1K ﹤0.01% 7299
2025
Q3 		$988 Sell
202
-3,553
-95% -$18.1K ﹤0.01% 9464
2025
Q2 		$22.2K Buy
3,755
+2,979
+384% +$15.8K ﹤0.01% 8365
2025
Q1 		$4.52K Buy
+776
New +$5.36K ﹤0.01% 9095
2024
Q3 		– Sell
-2,361
Closed -$19.8K – 9940
2024
Q2 		$19.8K Buy
2,361
+1,716
+266% +$13.8K ﹤0.01% 7312
2024
Q1 		$5.5K Buy
+645
New +$5.38K ﹤0.01% 7532
2023
Q1 		– Sell
-2,066
Closed -$22.5K – 10202
2022
Q4 		$22.5K Sell
2,066
-3,878
-65% -$21.1K ﹤0.01% 7535
2022
Q3 		$24K Buy
5,944
+5,739
+2,800% +$38.7K ﹤0.01% 7153
2022
Q2 		$1K Buy
+205
New +$1.62K ﹤0.01% 9933
2022
Q1 		– Sell
-1,428
Closed -$16K – 10755
2021
Q4 		$16K Buy
+1,428
New +$17.8K ﹤0.01% 8173
2021
Q2 		– Sell
-300
Closed -$6K – 9717
2021
Q1 		$6K Sell
300
-2,000
-87% -$48K ﹤0.01% 8248
2020
Q4 		$47K Sell
2,300
-492
-18% -$9.05K ﹤0.01% 6246
2020
Q3 		$49K Buy
2,792
+322
+13% +$5.12K ﹤0.01% 5667
2020
Q2 		$42K Sell
2,470
-1,075
-30% -$13.6K ﹤0.01% 6011
2020
Q1 		$34K Buy
3,545
+2,845
+406% +$36.9K ﹤0.01% 6122
2019
Q4 		$8K Buy
+700
New +$6.45K ﹤0.01% 7395

Other funds holding PROF

Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $349M AUM 28.06% 1-Year Est. Return
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ZCP
Z3 Capital Partners Richmond, Virginia $476M AUM
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.77B AUM 38.11% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

UBS Group's PROF Position: Q2 2026 in Review

UBS Group reduced its Profound Medical (PROF) stake by 32% in Q2 2026, selling an estimated $174K and leaving 55,224 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #6430.

UBS Group first reported a position in PROF in Q4 2019 and has held it in 18 quarters since. The position peaked at $526K in Q1 2026. 56 funds tracked by Wall St. Rank hold PROF as of Q2 2026.

  • UBS Group held 55,224 shares of Profound Medical worth $367K as of Q2 2026.
  • UBS Group sold 25,884 Profound Medical shares in Q2 2026, an estimated $174K.
  • Profound Medical made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6430 holding.
  • UBS Group first reported a position in Profound Medical in Q4 2019 and has held it in 18 quarters since.
  • UBS Group's Profound Medical position peaked at $526K in Q1 2026.
  • 56 funds tracked by Wall St. Rank held Profound Medical as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.